摘要
目的:探讨血清中细胞因子变化在恶性淋巴瘤(ML)中的意义。方法:采用放射免疫分析法及酶联免疫吸附法测定了49例ML患者血清中白细胞介素2(IL-2)等5种细胞因子浓度。结果:除肿瘤坏死因子α(TNFα)外,大部分初治、复发患者中治疗前IL-2,可溶性白细胞介素2受体(sIL-2R),IL-6,IL-8升高;治疗有反应的下降,完全缓解时与对照组无差异;治疗无反应的仍保持高水平。IL-2及sIL-2R升高与患者的临床分期有关,Ⅲ、Ⅳ期患者较Ⅰ、Ⅱ期明显增高;sIL-2R与肿瘤负荷有关;IL-6与患者有无B组症状相关,B组患者明显高于A组,而与分期无关;IL-8升高与临床分期及B组症状有关,与其他临床血液学指标无关。结论:细胞因子的变化可以作为观察ML病情及监测治疗反应的一种手段。
Objective:To study the clinical significance of serum cytokine levels in patients with malignant lymphoma(ML).Methods:Serum levels of five cytokines and receptor were measured in 49 patients with ML by RIA and ELISA.Results:Except TNFα,significantly higher pretreatment levels of interleukin2(IL2),soluble interleukin2 receptor(sIL2R), interleukin6(IL6) and interleukin8(IL8) were observed in most of ML patients at diagnosis or relapse as compared with controls(P<0.05). Cytokine levels declined in responding patients after therapy and there were no differences between CR cases and controls,the cytokine levels remained elevated in nonresponding patients. The levels of IL2 and sIL2R correlated with the clinical stage , which were significantly higher in patients in stage Ⅲ、Ⅳ.The increase of sIL2R correlated with the tumor burden.The level of IL6 was higher in patients presenting B symptoms and had no correlation with the clinical stage.The elevated IL8 level correlated with the clinical stage and presenting B symptoms of ML patients and had no correlation with other clinicalhematological parameters.Conclusion:The changes of cytokines may be served as a means to observe the condition of ML patients and supervise their response to treatment.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1998年第2期85-88,共4页
Chinese Journal of Hematology